Related references
Note: Only part of the references are listed.Advances in Analyses of Profens in Biological and Environmental Samples by Liquid Chromatography
Imran Ali et al.
CURRENT PHARMACEUTICAL ANALYSIS (2016)
Nanosponges: A Novel Class of Drug Delivery System - Review
Selvamuthukumar S et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2016)
Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy
Mallesh Kurakula et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2015)
Development and Evaluation of Solid Self Nano-Emulsifying Formulation of Rosuvastatin Calcium for Improved Bioavailability
Nilesh S. Kulkarni et al.
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH (2015)
Differential Metabolic Actions of Specific Statins: Clinical and Therapeutic Considerations
Soo Lim et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
Controlled drug delivery systems: Past forward and future back
Kinam Park
JOURNAL OF CONTROLLED RELEASE (2014)
Prevalence of Dyslipidemia in Urban and Rural India: The ICMR-INDIAB Study
Shashank R. Joshi et al.
PLOS ONE (2014)
Prodrugs: A challenge for the drug development
Jolanta B. Zawilska et al.
Pharmacological Reports (2014)
Stability of nanosuspensions in drug delivery
Yancai Wang et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Formulation design and evaluation of a self-microemulsifying drug delivery system of lovastatin
Urvashi Goyal et al.
ACTA PHARMACEUTICA (2012)
Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability
Ankush Choudhary et al.
ACTA PHARMACEUTICA SINICA B (2012)
Studies in Dissolution Enhancement of Ezetimibe by Solid Dispersions in Combination with a Surface Adsorbent
Komal R. Parmar et al.
DISSOLUTION TECHNOLOGIES (2011)
Polymeric nanosponges as an alternative carrier for improved retention of econazole nitrate onto the skin through topical hydrogel formulation
Renuka Sharma et al.
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY (2011)
Emerging drugs for hyperlipidemia
Christos Paras et al.
EXPERT OPINION ON EMERGING DRUGS (2010)
Protein-nanoparticle conjugates as potential therapeutic agents for the treatment of hyperlipidemia
V. D. Maximov et al.
NANOTECHNOLOGY (2010)
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
Ian Hamilton-Craig et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2010)
Statin Adverse Effects A Review of the Literature and Evidence for a Mitochondrial Mechanism
Beatrice A. Golomb et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2008)
Circadian expression of FGF21 is induced by PPARα activation in the mouse liver
Katsutaka Oishi et al.
FEBS LETTERS (2008)
Nanoparticles in medicine: Therapeutic applications and developments
L. Zhang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Hypercholesterolaemia and its management
Deepak Bhatnagar et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
The biology and chemistry of hyperlipidemia
Kishor S. Jain et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Hypertriglyceridemia: its etiology, effects and treatment
George Yuan et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2007)
Preparation and in vivo evaluation of SMEDDS (Self-Microemulsifying Drug Delivery System) containing fenofibrate
Ashok R. Patel et al.
AAPS JOURNAL (2007)
Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia
Yong S. K. Moon et al.
DRUGS OF TODAY (2007)
Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy
Juan Tamargo et al.
PHARMACOLOGY & THERAPEUTICS (2007)
Protective effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on copper-induced hydroxyl radical generation in the rat heart
Toshio Obata
TOXICOLOGY (2006)
A new approach in gastroretentive drug delivery system using cholestyramine
RB Umamaheshwari et al.
DRUG DELIVERY (2003)
Pharmacologic characteristics of statins
JM McKenney
CLINICAL CARDIOLOGY (2003)
Fenofibrate in the treatment of dyslipidemia: A review of the data as they relate to the new suprabioavailable tablet formulation
J Najib
CLINICAL THERAPEUTICS (2002)
Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers
PD Martin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia
MH Davidson
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2002)
Lipid-lowering drugs: Are adverse effects predictable and reversible?
A Muscari et al.
CARDIOLOGY (2002)
High-density lipoprotein: Epidemiology, metabolism, and antiatherogenic effects
PP Toth
DM DISEASE-A-MONTH (2001)
NK-104: a novel synthetic HMG-CoA reductase inhibitor
K Kajinami et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000)
Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors -: The role of metabolism -: Monograph for physicians
M Bottorff
ARCHIVES OF INTERNAL MEDICINE (2000)
Current perspectives on statins
DJ Maron et al.
CIRCULATION (2000)
Share Paper
